After three decades of antiretroviral therapy, HIV has changed from being a lethal disease to a chronic condition, mostly due to drastic improvements in antiretrovirals (ARVs). In a constant evolving field, understanding the drug interactions, the clinical pharmacology and having up-to-date information on clinical practices is essential for designing optimal treatment strategies leading to better treatment outcomes.
Excellence in ARV treatment has a direct impact on the efficacy and tolerability obtained in the quality of life of HIV-infected subjects and the cost-efficacy of treatment budgets in the HIV disease. As information evolves quickly, timely updates of the topics with clinical impact on antiretroviral treatment strategies and drug choice are a must.
Additionally, as a result of the significantly improved prognosis for HIV-infected patients, AIDS-related mortality has decreased but non-AIDS comorbidities and toxicity issues have emerged and being up-to-date on the clinical impact of the most significant ones is key.
On the other hand, we are moving towards the elimination of HIV transmission, prevention strategies are now available such as Pre-exposure Prophylaxis (PrEP) which is a hot topic of overwhelming interest that will be addressed in this workshop and long-acting ARTs.